Angioplasty, Angioplasty, Balloon, Coronary, Coronary Angiography, Coronary Artery Disease, Humans, Stents, Treatment Outcome
Conditions
Brief summary
This is a First In Man study with the aim to know the safety and effectiveness of a novel bare metal stent (INC-1) in the treatment of de novo coronary lesions in patients with stable coronary angina and unique coronary lessions.
Detailed description
The cost of performing a percutaneous coronary intervention is very variable since a large number of materials and human resources are considered, with the Stent cost being a fundamental factor; in developing countries, the cost this technology represents an important expense for the patient and the health system; which promotes the development of local technology to support the requirement of these devices. Ischemic heart disease together with cerebral vascular events is the main cause of, adding 15 million deaths per year. Percutaneous revascularization is the gold standard choice in many of the variants of presentation of ischemic heart disease, the implantation of Stents is the most used method. Nowadays more and more countries start their own research and development of novel devices in order to reduce cost. Research question: Is the INC1 Bare Metal Stent safe and effective for the treatment of de novo coronary lesions in humans? Hypothesis: The INC1 Bare-metal Stent is safe and effective for the treatment of de novo coronary lesions in humans The INC1 Bare metal Stent is a 70uCoCr
Interventions
DEVICEStent INC1
Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
Sponsors
GSE Biomedical
Medstent SA de CV.
Instituto Nacional de Cardiologia Ignacio Chavez
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Both genders. * From 18 to 75 years * Stable ischemic heart disease. * Live less than 300 km from the Institution * Single coronary artery disease with a single coronary lesion * Stenosis of 50 to 90% of the lumen of the vessel to be treated. * Lesions less than 20 mm long * Reference lumen of the vessel to be treated greater than 2.5mm and less than 4.5mm
Exclusion criteria
* Left main disease. * Lesions greater than 90% of the lumen. * Non-dilatable lesion with conventional balloons. * Contraindication for dual antiplatelet therapy. * Creatinine clearance less than 45ml / min. * Calcification from moderate to severe. * Multivessel coronary artery disease. * Chronic total occlusion. * Cardiogenic shock or hemodynamic instability. * Left ventricular ejection fraction less than 30%. * Valvular disease of moderate to severe. * Coronary disease in bifurcation. * Probable or definite presence of thrombus in the lesion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of late lumen loss [Safety and Tolerability]) | 9 months | The primary endpoint of the study is angiographic in-stent late lumen loss (LLL), defined as the difference between the post-procedural minimal lumen diameter (MLD) in the stented segment and the MLD in the same segment at follow-up measured by the angiography laboratory. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Need of Revascularization | 9 months | The Need of Revascularization of the treated vessel with a new angioplasty |
| MACE | 9 months | To evaluate the presence of major adverse cardiovascular events such (MACE) as cardiac death, myocardial infarction, new angina event or revascularization through surgery. |
| Hyperplasia | 9 months | To evaluate the degree of neointimal hyperplasia or at 9 months by intracoronary ultrasound. |
Countries
Mexico
Outcome results
None listed